Recent Investment Analysts’ Ratings Changes for Alnylam Pharmaceuticals (ALNY)

A number of research firms have changed their ratings and price targets for Alnylam Pharmaceuticals (NASDAQ: ALNY):

• 10/23/2026 – Alnylam Pharmaceuticals was downgraded by Zacks Research from “strong-buy” to “hold”.
• 10/15/2026 – Alnylam Pharmaceuticals is now covered by UBS Group. They set a “buy” rating and a $354.00 price target on the stock.
• 10/14/2026 – Alnylam Pharmaceuticals was upgraded by UBS Group to “strong-buy”.
• 10/14/2026 – Alnylam Pharmaceuticals had its price target lowered by Citigroup from $340.00 to $320.00. They now have a “buy” rating on the stock.
• 10/14/2026 – Alnylam Pharmaceuticals had its price target lowered by Wells Fargo & Company from $256.00 to $253.00. They now have an “equal weight” rating on the stock.
• 10/8/2026 – Alnylam Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $350.00 to $345.00. They now have an “outperform” rating on the stock.
• 10/5/2026 – Alnylam Pharmaceuticals was upgraded by Zacks Research from “hold” to “strong-buy”.
• 9/30/2026 – Alnylam Pharmaceuticals had its “neutral” rating reaffirmed by Cantor Fitzgerald.
• 9/30/2026 – Alnylam Pharmaceuticals had its price target lowered by JPMorgan Chase & Co. from $375.00 to $369.00. They now have an “overweight” rating on the stock.
• 9/21/2026 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $455.00 price target on the stock.
• 9/8/2026 – Alnylam Pharmaceuticals had its price target raised by Jefferies Financial Group from $230.00 to $260.00. They now have a “hold” rating on the stock.
• 9/2/2026 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $455.00 price target on the stock.
• 8/31/2026 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by Sanford C. Bernstein.
• 8/31/2026 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by TD Cowen.
• 8/31/2026 – Alnylam Pharmaceuticals had its “outperform” rating reaffirmed by BMO Capital Markets.

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Bryan Supran sold 1,758 shares of the stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $226.88, for a total transaction of $398,855.04. Following the transaction, the executive vice president owned 12,807 shares of the company’s stock, valued at approximately $2,905,652.16. This represents a 12.07% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.